Ricardo Dolcetti

List of Publications by Year
in descending order

313	12,419	28190	33814
papers	citations	55 h-index	99 g-index

323	323	323	15447
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2004, 96, 586-594.	3.0	533
2	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
4	High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability. American Journal of Pathology, 1999, 154, 1805-1813.	1.9	425
5	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
6	Microsatellite Instability and High Content of Activated Cytotoxic Lymphocytes Identify Colon Cancer Patients with a Favorable Prognosis. American Journal of Pathology, 2001, 159, 297-304.	1.9	275
7	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science, 1993, 260, 98-100.	6.0	272
8	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
9	Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.. Journal of Clinical Oncology, 1995, 13, 1758-1767.	0.8	217
10	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. Blood, 1997, 90, 776-782.	0.6	217
11	Regression of Ocular Adnexal Lymphoma AfterChlamydia Psittaciâ€“Eradicating Antibiotic Therapy. Journal of Clinical Oncology, 2005, 23, 5067-5073.	0.8	211
12	Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial. Journal of the National Cancer Institute, 2006, 98, 1375-1382.	3.0	201
13	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-1892.	0.6	174
14	Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2988-2994.	0.8	167
15	Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. Journal of Virology, 1993, 67, 1572-1578.	1.5	164
16	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 1995, 86, 1493-1501.	0.6	160
17	Human Herpesvirus 8 Is Present in the Lymphoid System of Healthy Persons and Can Reactivate in the Course of AIDS. Journal of Infectious Diseases, 1996, 173, 542-549.	1.9	159
18	High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 1992, 7, 1159-66.	2.6	149

#	Article	IF	Citations
19	p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: Genetic and prognostic implications. International Journal of Cancer, 1992, 52, 178-182.	2.3	143
20	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood, 2008, 111, 5142-5151.	0.6	142
21	Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Frontiers in Oncology, 2018, 8, 322.	1.3	137
22	The epstein-barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in burkitt lymphoma lines. International Journal of Cancer, 1994, 57, 240-244.	2.3	132
23	Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 2020, 180, 895-914.e27.	13.5	127
24	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. Journal of Infectious Diseases, 1994, 170, 211-215.	1.9	121
25	Virologic and Immunologic Evidence Supporting an Association between HHV-6 and Hashimoto's Thyroiditis. PLoS Pathogens, 2012, 8, e1002951.	2.1	121
26	Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. Cancer Letters, 2015, 369, 37-44.	3.2	118
27	Human herpesviruses 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. Journal of Medical Virology, 1995, 45, 462-468.	2.5	108
28	Lymphomas occurring specifically in HIV-infected patients: From pathogenesis to pathology. Seminars in Cancer Biology, 2013, 23, 457-467.	4.3	102
29	Characterization of prelymphomatous stages of B cell lymphoproliferation in SjÃ¶gren's syndrome. Arthritis and Rheumatism, 1997, 40, 318-331.	6.7	100
30	A lymphomagenic role for HIV beyond immune suppression?. Blood, 2016, 127, 1403-1409.	0.6	99
31	Congenital cytomegalovirus infection: patterns of fetal brain damage. Clinical Microbiology and Infection, 2012, 18, E419-E427.	2.8	96
32	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Annals of Oncology, 2008, 19, 835-846.	0.6	93
33	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
34	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
35	The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica, 2010, 95, 1769-1777.	1.7	89
36	Chlamydia Infection and Lymphomas: Association Beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods. Clinical Cancer Research, 2008, 14, 5794-5800.	3.2	83

#	Article	IF	Citations
37	Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. European Journal of Cancer, 2001, 37, 1276-1287.	1.3	81
38	B lymphocytes and Epsteinâ€“Barr virus: The lesson of post-transplant lymphoproliferative disorders. Autoimmunity Reviews, 2007, 7, 96-101.	2.5	79
39	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
40	Simian-virus-40 footprints in human lymphoproliferative disorders of HIVâˆ’ and HIV+ patients. International Journal of Cancer, 1998, 78, 669-674.	2.3	75
41	Familial breast cancer: characteristics and outcome of BRCA 1â€“2 positive and negative cases. BMC Cancer, 2005, 5, 70.	1.1	73
42	Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy. Journal of Clinical Investigation, 2018, 128, 1971-1984.	3.9	73
43	Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Annals of Oncology, 2006, 17, 769-772.	0.6	71
44	Epstein-Barr virus: Induction and control of cell transformation. Journal of Cellular Physiology, 2003, 196, 207-218.	2.0	69
45	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
46	Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica, 2005, 90, 1578-9.	1.7	67
47	Chlamydophila psittaciis viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a singleâ€center prospective caseâ€“control study. International Journal of Cancer, 2008, 123, 1089-1093.	2.3	66
48	Latent Membrane Protein 1 of Epstein-Barr Virus Activates the hTERT Promoter and Enhances Telomerase Activity in B Lymphocytes. Journal of Virology, 2008, 82, 10175-10187.	1.5	65
49	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Journal of Translational Medicine, 2015, 13, 204.	1.8	64
50	Proposed Molecular and miRNA Classification of Gastric Cancer. International Journal of Molecular Sciences, 2018, 19, 1683.	1.8	64
51	Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunology, Immunotherapy, 2006, 55, 23-30.	2.0	63
52	Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas. Oncologist, 2011, 16, 1582-1588.	1.9	61
53	Molecular profile of Epsteinâ€“Barr virus infection in HHV-8-positive primary effusion lymphoma. Leukemia, 2000, 14, 271-277.	3.3	60
54	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	3.3	58

#	Article	IF	Citations
55	Chlamydial infection: the link with ocular adnexal lymphomas. Nature Reviews Clinical Oncology, 2009, 6, 658-669.	12.5	57
56	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
57	Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: A comparative study. Human Pathology, 1996, 27, 133-146.	1.1	56
58	Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. Seminars in Cancer Biology, 2013, 23, 441-456.	4.3	56
59	Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer. Frontiers in Immunology, 2017, 8, 1476.	2.2	54
60	High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. FEBS Journal, 1993, 213, 825-832.	0.2	53
61	Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Clinical Cancer Research, 2003, 9, 743-8.	3.2	52
62	Prevalence ofBRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectableBRCA1 andBRCA2 point mutations. Genes Chromosomes and Cancer, 2006, 45, 791-797.	1.5	50
63	Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis and Rheumatism, 1995, 38, 867-868.	6.7	48
64	Association betweenHelicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematological Oncology, 2006, 24, 33-37.	0.8	48
65	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. International Journal of Molecular Sciences, 2018, 19, 1602.	1.8	48
66	Re: Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2006, 98, 365-366.	3.0	47
67	Role of CD4⁺Cytotoxic T Lymphocytes in the Control of Viral Diseases and Cancer. International Reviews of Immunology, 2010, 29, 371-402.	1.5	47
68	B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome.. Annals of the Rheumatic Diseases, 1996, 55, 311-316.	0.5	46
69	Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases. Journal of Immunology, 2000, 164, 2815-2822.	0.4	46
70	The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer, 2017, 140, 1233-1245.	2.3	46
71	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virusâ€“Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	0.6	46
72	Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. Leukemia, 2012, 26, 814-821.	3.3	45

#	Article	IF	Citations
73	Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas. Seminars in Cancer Biology, 2015, 34, 58-69.	4.3	45
74	Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood, 1997, 90, 776-82.	0.6	45
75	BRCA1 andBRCA2 genes: Role in hereditary breast and ovarian cancer in Italy. , 1999, 83, 5-9.		44
76	High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell ki-1-positive lymphomas in HIV-1-positive patients. International Journal of Cancer, 1993, 54, 53-59.	2.3	43
77	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. Journal of Immunology, 2010, 184, 5895-5902.	0.4	43
78	GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle, 2008, 7, 2813-2816.	1.3	42
79	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1356964.	2.1	42
80	Widespread clonal B-cell disorder in Sjogren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. Gastroenterology, 1996, 110, 1969-1974.	0.6	41
81	Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Human Immunology, 2012, 73, 502-510.	1.2	41
82	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology, 2012, 132, 2652-2660.	0.3	41
83	Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opinion on Biological Therapy, 2008, 8, 1265-1294.	1.4	40
84	Isolated Bone Marrow Manifestation of HIV-Associated Hodgkin Lymphoma. Modern Pathology, 2002, 15, 1273-1278.	2.9	39
85	Infectious Agents in Mucosa-Associated Lymphoid Tissueâ€“Type Lymphomas: Pathogenic Role and Therapeutic Perspectives. Clinical Lymphoma and Myeloma, 2006, 6, 289-300.	1.4	39
86	Elevated Serum Transforming Growth Factor Î²1 Levels in Epstein-Barr Virus-Associated Diseases and Their Correlation with Virus-Specific Immunoglobulin A (IgA) and IgM. Journal of Virology, 2000, 74, 2443-2446.	1.5	38
87	Chlamydia psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. Annals of Oncology, 2008, 19, 194-195.	0.6	38
88	Clinical value of Epsteinâ€“Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. Cancer Letters, 2006, 233, 247-254.	3.2	37
89	Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?. Anti-Cancer Drugs, 2008, 19, 761-765.	0.7	37
90	Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells. Cell Death and Disease, 2016, 7, e2562-e2562.	2.7	36

#	Article	IF	Citations
91	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-92.	0.6	36
92	Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?. Infectious Agents and Cancer, 2010, 5, 22.	1.2	34
93	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
94	Microenvironment and HIV-related lymphomagenesis. Seminars in Cancer Biology, 2015, 34, 52-57.	4.3	34
95	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. International Journal of Cancer, 2015, 137, 1374-1385.	2.3	34
96	Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells. Frontiers in Immunology, 2017, 8, 197.	2.2	34
97	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNÎ±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	3.2	34
98	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus- immortalized B lymphocytes. Blood, 1996, 88, 3147-3159.	0.6	33
99	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	1.9	33
100	hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: Implications for EBV-driven lymphomagenesis. International Journal of Cancer, 2007, 121, 576-587.	2.3	33
101	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Research, 2005, 65, 587-95.	0.4	33
102	Is the Epstein-Barr Virus Involved in Hodgkin's Disease?. Tumori, 1989, 75, 345-350.	0.6	32
103	Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event. Oncogene, 1998, 17, 1827-1836.	2.6	32
104	Spontaneous T cell responses to Epsteinâ€Barr virusâ€encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. International Journal of Cancer, 2008, 123, 1100-1107.	2.3	32
105	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 58.	1.8	32
106	The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. Journal of Experimental and Clinical Cancer Research, 2002, 21, 115-24.	0.4	32
107	Exploiting the Interplay between Innate and Adaptive Immunity to Improve Immunotherapeutic Strategies for Epstein-Barr-Virus-Driven Disorders. Clinical and Developmental Immunology, 2012, 2012, 1-19.	3.3	31
108	A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas. Journal of the National Cancer Institute, 2007, 99, 1418-1419.	3.0	30

#	Article	IF	Citations
109	A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Research, 2011, 13, R117.	2.2	30
110	Telomere/telomerase interplay in virusâ€driven and virusâ€independent lymphomagenesis: pathogenic and clinical implications. Medicinal Research Reviews, 2012, 32, 233-253.	5.0	30
111	The Epstein-Barr Virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. , 1998, 79, 481-486.		29
112	Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2009, 9, 113-131.	0.6	29
113	Immunotherapy for EBV-associated malignancies. International Journal of Hematology, 2011, 93, 281-293.	0.7	29
114	The polymerase chain reaction detects B cell clonalities in patients with SjÃ¶gren's syndrome and suspected malignant lymphoma. Journal of Rheumatology, 1994, 21, 1497-501.	1.0	29
115	Simian Virus 40 Sequences in Human Lymphoblastoid B-Cell Lines. Journal of Virology, 2003, 77, 1595-1597.	1.5	28
116	Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death and Disease, 2015, 6, e1774-e1774.	2.7	28
117	Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients. Frontiers in Oncology, 2019, 9, 160.	1.3	28
118	Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives. Current Cancer Drug Targets, 2011, 11, 85-102.	0.8	27
119	Retinoic Acid/Alpha-Interferon Combination Inhibits Growth and Promotes Apoptosis in Mantle Cell Lymphoma through Akt-Dependent Modulation of Critical Targets. Cancer Research, 2012, 72, 1825-1835.	0.4	27
120	hTERT Inhibition Triggers Epsteinâ€“Barr Virus Lytic Cycle and Apoptosis in Immortalized and Transformed B Cells: A Basis for New Therapies. Clinical Cancer Research, 2013, 19, 2036-2047.	3.2	27
121	Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles. Human Immunology, 2004, 65, 1397-1404.	1.2	26
122	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
123	Local cytokine expression in the progression toward B cell malignancy in SjÃ¶gren's syndrome. Journal of Rheumatology, 1995, 22, 1674-80.	1.0	26
124	Human herpesvirus 6 in human immunodeficiency virus-infected individuals: Association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders. , 1996, 48, 344-353.		25
125	Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. Clinical Epigenetics, 2015, 7, 89.	1.8	25
126	Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. Annals of Oncology, 1992, 3, 307-310.	0.6	24

#	Article	IF	Citations
127	Subtypes of epstein-barr virus in HIV-1-associated and HIV-1-unrelated hodgkin's disease cases. International Journal of Cancer, 1993, 54, 895-898.	2.3	24
128	Low incidence ofBRCA1 mutations among Italian families with breast and ovarian cancer. International Journal of Cancer, 1998, 78, 581-586.	2.3	24
129	Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget, 2016, 7, 57327-57350.	0.8	24
130	Demonstration of a unique Epstein-Barr virus-positive cellular clone in metachronous multiple localizations of Hodgkin's disease. American Journal of Pathology, 1993, 142, 33-8.	1.9	24
131	Characteristics of EBV-infected cells in HIV-related lymphadenopathy: Implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals. International Journal of Cancer, 1995, 63, 652-659.	2.3	23
132	Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Matrix Proteins Specify Different Capabilities To Modulate B Cell Growth. Journal of Virology, 2014, 88, 5706-5717.	1.5	23
133	Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. Expert Review of Hematology, 2017, 10, 505-514.	1.0	23
134	Enhancing chimeric antigen receptor Tâ€cell immunotherapy against cancer using a nanoemulsionâ€based vaccine targeting crossâ€presenting dendritic cells. Clinical and Translational Immunology, 2020, 9, e1157.	1.7	23
135	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. Blood, 1997, 90, 776-782.	0.6	23
136	Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 1995, 86, 1493-501.	0.6	23
137	Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins. Oncogene, 2005, 24, 2483-2494.	2.6	22
138	HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens, 2010, 75, 127-135.	1.0	22
139	Retinoic acid induces persistent, RAR?-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines. , 2000, 86, 375-384.		21
140	High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance. Infectious Agents and Cancer, 2007, 2, 5.	1.2	21
141	B-Cell Lymphomas Associated With HCV Infection. Gastroenterology, 2007, 132, 1205-1207.	0.6	21
142	Reverse immunoediting: When immunity is edited by antigen. Immunology Letters, 2016, 175, 16-20.	1.1	21
143	N-myc activation by proviral insertion in MCF 247-induced murine T-cell lymphomas. Oncogene, 1989, 4, 1009-14.	2.6	21
144	Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Digestive and Liver Disease, 2007, 39, S65-S71.	0.4	20

#	Article	IF	Citations
145	Role of the HLA Class II: HCV-Related Disorders. Annals of the New York Academy of Sciences, 2007, 1107, 308-318.	1.8	19
146	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Cancer Immunology Research, 2016, 4, 431-440.	1.6	19
147	An ExÂVivo Human Tumor Assay Shows DistinctÂPatterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. Journal of Investigative Dermatology, 2019, 139, 213-223.	0.3	19
148	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. British Journal of Cancer, 1993, 67, 674-679.	2.9	18
149	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. International Journal of Cancer, 2009, 125, 1358-1364.	2.3	18
150	Central nervous system marginal zone B-cell lymphoma associated with Chlamydophila psittaci infection. Human Pathology, 2011, 42, 738-742.	1.1	18
151	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
152	Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. Hereditary Cancer in Clinical Practice, 2017, 15, 16.	0.6	18
153	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. Tumori, 1995, 81, 405-409.	0.6	17
154	Activation of Infiltrating Cytotoxic T Lymphocytes and Lymphoma Cell Apoptotic Rates in Gastric MALT Lymphomas. American Journal of Pathology, 1999, 155, 823-829.	1.9	17
155	Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases. International Journal of Molecular Sciences, 2019, 20, 1280.	1.8	17
156	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget, 0, 7, 41913-41928.	0.8	17
157	Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Research, 1995, 55, 3675-81.	0.4	17
158	Retinoic Acid Analogues Inhibit Human Herpesvirus 8 Replication. Antiviral Therapy, 2008, 13, 199-210.	0.6	17
159	Characterization of Epsteinâ€“Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. AIDS Research and Human Retroviruses, 2002, 18, 19-26.	0.5	16
160	Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy. BMC Medical Genetics, 2016, 17, 11.	2.1	16
161	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget, 2016, 7, 37487-37497.	0.8	16
162	High prevalence of Chlamydophila psittaci subclinical infection in Italian patients with SjÃ¶gren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. Clinical and Experimental Rheumatology, 2014, 32, 61-5.	0.4	16

#	Article	IF	Citations
163	Nuclear oncogene amplification or rearrangement is not involved in human colorectal malignancies. European Journal of Cancer & Clinical Oncology, 1988, 24, 1321-1328.	0.9	15
164	Genetic and epigenetic changes linked to Chlamydophila psittaciâ€associated ocular adnexal lymphomas. Hematological Oncology, 2010, 28, 1-2.	0.8	15
165	A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17. Scientific Reports, 2017, 7, 6555.	1.6	15
166	Epstein-Barr Virus Strains With Latent Membrane Protein-1 Deletions: Prevalence in the Italian Population and High Association With Human Immunodeficiency Virusâ€"Related Hodgkin's Disease. Blood, 1997, 89, 1723-1731.	0.6	15
167	Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. PLoS ONE, 2016, 11, e0153823.	1.1	15
168	Cancer, Aging and Immune Reconstitution. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1310-1324.	0.9	15
169	Epstein-Barr virus in the pathogenesis of Hodgkin's disease. Biomedicine and Pharmacotherapy, 1998, 52, 13-25.	2.5	14
170	Bidirectional induction of the cognate receptor-ligand Î±4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-2406.	0.6	14
171	Latent Membrane Protein 1 Deletion Mutants Accumulate in Reed-Sternberg Cells of Human Immunodeficiency Virus-Related Hodgkin's Lymphoma. Journal of Virology, 2005, 79, 2643-2649.	1.5	14
172	Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial. Annals of Oncology, 2006, 17, 1721-1722.	0.6	14
173	Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells. Clinical and Experimental Immunology, 2007, 148, 402-409.	1.1	14
174	IGKV3 Proteins as Candidate â€œOff-the-Shelfâ€•Vaccines for Kappa-Light Chainâ€"Restricted B-Cell Non-Hodgkin Lymphomas. Clinical Cancer Research, 2012, 18, 4080-4091.	3.2	14
175	Glucocorticoids promote the proliferation and antagonize the retinoic acidâ€"mediated growth suppression of Epstein-Barr virusâ€"immortalized B lymphocytes. Blood, 2000, 96, 711-718.	0.6	13
176	Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer, 2006, 6, 156.	1.1	13
177	Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae. British Journal of Cancer, 2012, 106, 966-969.	2.9	13
178	Serologic investigation of undifferentiated nasopharyngeal carcinoma and simian virus 40 infection. Head and Neck, 2016, 38, 232-236.	0.9	13
179	A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. OncoImmunology, 2017, 6, e1304338.	2.1	13
180	Protein glycosylation in head and neck cancers: From diagnosis to treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188422.	3.3	13

#	Article	IF	Citations
181	Aids-related B-cell non-Hodgkin's lymphomas in direct blood-stream HIV-infected patients: Pathogenesis and differentiation features. International Journal of Cancer, 1990, 45, 883-888.	2.3	12
182	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients [letter; comment]. Blood, 1993, 82, 328-330.	0.6	12
183	Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. , 1999, 80, 240-249.		12
184	Characterization of Antibodies Directed against the Immunoglobulin Light Îº Chain Variable Chain Region (VK) of Hepatitis C Virusâ€Related Typeâ€I Mixed Cryoglobulinemia and Bâ€Cell Proliferations. Annals of the New York Academy of Sciences, 2009, 1173, 152-160.	1.8	12
185	Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. Journal of Translational Medicine, 2010, 8, 18.	1.8	12
186	Breast Cancer and Simian Virus 40 Infection. Epidemiology, 2013, 24, 464-465.	1.2	12
187	Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 2021, 13, 3733.	1.7	12
188	Retinoic acid analogues inhibit human herpesvirus 8 replication. Antiviral Therapy, 2008, 13, 199-209.	0.6	12
189	Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. Lancet, The, 1994, 344, 543.	6.3	11
190	EBV-Associated Tumors: Pathogenetic Insights for Improved Disease Monitoring and Treatment. Current Cancer Therapy Reviews, 2005, 1, 27-44.	0.2	11
191	Epstein-Barr virus and telomerase: from cell immortalization to therapy. Infectious Agents and Cancer, 2014, 9, 8.	1.2	11
192	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy - Methods and Clinical Development, 2021, 21, 592-606.	1.8	11
193	Type 2 Epstein-Barr Virus Genome and Latent Membrane Protein-1 Expression in a T-Cell-Rich Lymphoma of Probable B-Cell Lineage. American Journal of Clinical Pathology, 1993, 100, 541-549.	0.4	10
194	Serum Antibody Response to Lytic and Latent Epstein-Barr Virus Antigens in Undifferentiated Nasopharyngeal Carcinoma Patients from an Area of Nonendemicity. Vaccine Journal, 2007, 14, 435-441.	3.2	10
195	NKT Cellâ€“Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion. Cancer Immunology Research, 2019, 7, 952-962.	1.6	10
196	Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Advances in Cancer Research, 2003, 87, 127-157.	1.9	10
197	Is the Epstein-Barr virus involved in Hodgkin's disease?. Tumori, 1989, 75, 345-50.	0.6	10
198	Cellular and molecular bases of B-cell clonal expansions. Clinical and Experimental Rheumatology, 1996, 14 Suppl 14, S3-13.	0.4	10

#	Article	IF	Citations
199	Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx. European Archives of Oto-Rhino-Laryngology, 1991, 248, 279-85.	0.8	9
200	Transformation-Associated Epstein-Barr Virus Antigens as Targets for Immune Attack. Annals of the New York Academy of Sciences, 1993, 690, 86-100.	1.8	9
201	Detection of DNA ofChlamydophila psittaciin subjects with psoriasis: a casual or a causal link?. British Journal of Dermatology, 2012, 167, 926-928.	1.4	9
202	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	1.1	9
203	Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment. Cancer Medicine, 2019, 8, 3012-3016.	1.3	9
204	Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIVâ€infected patient. Hematological Oncology, 2019, 37, 176-184.	0.8	9
205	Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood, 1997, 89, 1723-31.	0.6	9
206	Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Human Vaccines and Immunotherapeutics, 2013, 9, 1078-1083.	1.4	8
207	Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. Journal of Translational Medicine, 2014, 12, 207.	1.8	8
208	Detection of HIV-1 Matrix Protein p17 Quasispecies Variants in Plasma of Chronic HIV-1â€“Infected Patients by Ultra-Deep Pyrosequencing. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 332-339.	0.9	8
209	What's New in the Biology and Treatment of Undifferentiated Carcinoma of Nasopharyngeal Type?. Acta Oto-Laryngologica, 2001, 121, 884-895.	0.3	8
210	Teaching digital pathology: The international school of digital pathology and proposed syllabus. Journal of Pathology Informatics, 2017, 8, 27.	0.8	8
211	In vivo phenotypic characteristics of AKR T-cell lymphomas with different leukemic potential: Possible role of Î±4Î²7 integrin in the progression towards the leukemic phenotype. International Journal of Cancer, 1994, 56, 560-567.	2.3	7
212	Inhibition of oxidative phosphorylation underlies the antiproliferative and proapoptotic effects of mofarotene (Ro 40-8757) in Burkitt's lymphoma cells. Oncogene, 2003, 22, 906-918.	2.6	7
213	Therapeutic management of ocular adnexal MALT lymphoma. Expert Opinion on Pharmacotherapy, 2007, 8, 1073-1083.	0.9	7
214	Prevalence of chlamydial infection in a series of 108 primary cutaneous lymphomas. British Journal of Dermatology, 2012, 166, 1121-1123.	1.4	7
215	Functional Avidityâ€“Driven Activation-Induced Cell Death Shapes CTL Immunodominance. Journal of Immunology, 2014, 193, 4704-4711.	0.4	7
216	Alpha 4 beta 7 integrin expression is associated with the leukemic evolution of human and murine T-cell lymphoblastic lymphomas. American Journal of Pathology, 1997, 150, 1595-605.	1.9	7

#	Article	IF	Citations
217	Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood, 1996, 88, 3147-59.	0.6	7
218	Bidirectional induction of the cognate receptor-ligand alpha4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-406.	0.6	7
219	Establishment and characterization of a leukemic murine cell line derived from MCF 247 MuLV-induced T-cell lymphoma. International Journal of Cancer, 1990, 45, 928-934.	2.3	6
220	Pathogenesis of Human Reactive-Appearing Â«Non-MonomorphousÂ» Malignant Lymphoproliferative Disorders: A Hypothesis. Tumori, 1992, 78, 221-227.	0.6	6
221	Target therapy in elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2012, 83, 422-431.	2.0	6
222	B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation. Cancer Gene Therapy, 2021, 28, 649-666.	2.2	6
223	Scientifically based combination therapies with immunoâ€oncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725.	1.1	6
224	Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 2021, 10, 425.	1.3	6
225	Association of Epstein-Barr Virus with Hodgkinâ€™s Disease. Infectious Agents and Pathogenesis, 1995, , 375-393.	0.1	6
226	The relevance of VDJ PCR protocols in detecting B-cell clonal expansion in lymphomas and other lymphoproliferative disorders. Tumori, 1995, 81, 405-9.	0.6	6
227	Chlamydophila psittaci subclinical infection in chronic polyarthritis. Clinical and Experimental Rheumatology, 2011, 29, 977-82.	0.4	6
228	Analysis of human leukocyte antigen associations in human papillomavirusâ€“positive and â€“negative head and neck cancer: Comparison with cervical cancer. Cancer, 2022, 128, 1937-1947.	2.0	6
229	A coordinated proto-oncogene expression characterizes MCF 247 murine leukemia virus-induced T-cell lymphomas irrespectively of proviral insertion affecting myc loci. Leukemia Research, 1990, 14, 549-558.	0.4	5
230	In VitroEffects of Retinoids on the Proliferation and Differentiation Features of Epstein-Barr Virus-Immortalized B Lymphocytes. Leukemia and Lymphoma, 1998, 29, 269-281.	0.6	5
231	Reply to the article â€˜Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)â€™ by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369). Annals of Oncology, 2007, 18, 401-403.	0.6	5
232	Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer Immunology, Immunotherapy, 2011, 60, 1639-1645.	2.0	5
233	Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells. Cancer Immunology, Immunotherapy, 2012, 61, 881-892.	2.0	5
234	A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. Aids, 2014, 28, 2355-2364.	1.0	5

#	Article	IF	Citations
235	Predictive Value of FcR Polymorphisms. JAMA Oncology, 2017, 3, 342.	3.4	5
236	Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?. Cancers, 2020, 12, 3392.	1.7	5
237	Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers in Immunology, 2020, 11, 507.	2.2	5
238	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. Blood, 2016, 128, 2976-2976.	0.6	5
239	Association between B-type Epstein-Barr virus and Hodgkin's disease in immunocompromised patients. Blood, 1993, 82, 328-30.	0.6	5
240	T cell receptor repertoire in B cell lymphoproliferative lesions in primary SjÃ¶gren's syndrome. Journal of Rheumatology, 1999, 26, 1101-9.	1.0	5
241	Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with SjÃ¶gren's syndrome and type II mixed cryoglobulinemia. Clinical and Experimental Rheumatology, 1999, 17, 339-42.	0.4	5
242	Degree of immune suppression and risk of HIV-related Hodgkin lymphoma: time points matter. Blood, 2009, 114, 2354-2354.	0.6	4
243	Impact of Î³-chain cytokines on EBV-specific T cell cultures. Journal of Translational Medicine, 2010, 8, 121.	1.8	4
244	Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy. Supportive Care in Cancer, 2011, 19, 733-735.	1.0	4
245	Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches. Cancer Treatment Reviews, 2021, 98, 102219.	3.4	4
246	Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders. PLoS ONE, 2012, 7, e44870.	1.1	4
247	Protein Expression Profile of Celiac Disease Patient with Aberrant T Cell by Two-dimensional Difference Gel Electrophoresis. Annals of the New York Academy of Sciences, 2007, 1109, 429-440.	1.8	3
248	Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers. BMC Cancer, 2009, 9, 360.	1.1	3
249	Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?. Blood, 2009, 114, 3499-3499.	0.6	3
250	Marginal zone B-cell lymphoma of the conjunctiva. Expert Review of Ophthalmology, 2010, 5, 177-188.	0.3	3
251	Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area. Pathology and Oncology Research, 2020, 26, 2459-2467.	0.9	3
252	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virusâ€related diseases. Liver International, 2021, 41, 133-149.	1.9	3

#	Article	IF	Citations
253	Glucocorticoids promote the proliferation and antagonize the retinoic acidâ€“mediated growth suppression of Epstein-Barr virusâ€“immortalized B lymphocytes. Blood, 2000, 96, 711-718.	0.6	3
254	Glucocorticoids promote the proliferation and antagonize the retinoic acid-mediated growth suppression of Epstein-Barr virus-immortalized B lymphocytes. Blood, 2000, 96, 711-8.	0.6	3
255	Genotypic and immunohistological demonstration of the progression of an unusual reactive-like B-cell lymphoproliferative disorder to a high grade diffuse lymphoma. Human Pathology, 1995, 26, 348-354.	1.1	2
256	Unconventional therapies in ocular adnexal lymphomas. Expert Review of Anticancer Therapy, 2010, 10, 1341-1343.	1.1	2
257	Polymerase chain reaction to assess B-cell clonality in clinical conditions at risk for B-cell malignancy. Transplantation Proceedings, 1994, 26, 3229-32.	0.3	2
258	Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10: 917-923, 2001. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 499; author reply 499-500.	1.1	2
259	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. International Journal of Oncology, 2004, 25, 345-55.	1.4	2
260	No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1819-20.	1.1	2
261	In-depth analysis of compartmentalization of HIV-1 matrix protein p17 in PBMC and plasma. New Microbiologica, 2017, 40, 58-61.	0.1	2
262	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 791958.	2.2	2
263	Genotypic and Immunophenotypic Characterization of Two Human Light Chainâ€“ â€“ Only B-Cell Non-Hodgkin's Lymphomas. American Journal of Clinical Pathology, 1990, 94, 390-396.	0.4	1
264	On the Biological Role of T-lymphocytes in T-cell-rich B-cell Lymphomas. American Journal of Clinical Pathology, 1995, 104, 231.1-231.	0.4	1
265	Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive or Both?. American Journal of Pathology, 2002, 160, 384-386.	1.9	1
266	Ruolo del virus di Epstein-Barr nella patogenesi dei disordini linfoproliferativi post-trapianto. Microbiologia Medica, 2003, 18, .	0.3	1
267	Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes. International Journal of Oncology, 2004, 25, 345.	1.4	1
268	Genetic and Epigenetic Mechanisms in Gastric Cancer. Current Clinical Pathology, 2019, , 25-40.	0.0	1
269	Immunomodulation and Immunotherapy for Gastric Cancer. Current Clinical Pathology, 2019, , 189-212.	0.0	1
270	Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA. Frontiers in Oncology, 2021, 11, 772348.	1.3	1

#	Article	IF	Citations
271	Chlamydia Psittaci-Eradicating Antibiotic Therapy as a Potential Therapeutic Strategy Against Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.. Blood, 2004, 104, 3274-3274.	0.6	1
272	Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	1
273	Adhesion molecule expression does not influence the leukemic behavior of murine T-cell lymphomas. Leukemia, 1992, 6 Suppl 3, 101S-105S.	3.3	1
274	Pathogenesis of malignant lymphomas in intravenous drug-abuser, HIV-infected patients. Cancer Detection and Prevention, 1990, 14, 661-8.	2.1	1
275	Can a specifically-aimed pathologic classification overcome the difficulties in defining HIV-associated lymphomas?. Pathologica, 1995, 87, 4-13.	1.3	1
276	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Frontiers in Oncology, 0, 12, .	1.3	1
277	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
278	An Eco RI restriction length polymorphism at the murine L-myc locus. Nucleic Acids Research, 1988, 16, 11853-11853.	6.5	0
279	Activation by Point Mutation of Ki-ras Gene Occurring in Transfected Human Normal dna. Tumori, 1988, 74, 499-506.	0.6	0
280	210 Phospholipid Scramblase 1 Sensitizes Mantle Cell Lymphoma to Apoptosis Induced by Several Drugs. European Journal of Cancer, 2012, 48, S51.	1.3	0
281	936 The Interplay Between Telomerase and Epstein Barr Virus (EBV) â€“Silencing of HTERT Induces the EBV Lytic Cycle. European Journal of Cancer, 2012, 48, S225.	1.3	0
282	1084 Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity. European Journal of Cancer, 2012, 48, S261.	1.3	0
283	1085 Generation of EBV-specific CTL Lines Enriched in BARF1 Specificities for Improved Adoptive Immunotherapy of Nasopharyngeal Carcinoma. European Journal of Cancer, 2012, 48, S261.	1.3	0
284	1086 IGHV1-69 as a Promising Candidate for the Development of a Shared Immunotherapy to B-cell Lymphomas. European Journal of Cancer, 2012, 48, S261-S262.	1.3	0
285	Ocular Adnexal Lymphoma of MALT-Type and Its Association with Chlamydophila psittaci Infection. , 2012, , 139-163.		0
286	Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Breast Cancer Patients: Investigating the Immune Profile to Identify Predictive Biomarkers. International Journal of Radiation Oncology Biology Physics, 2014, 90, S769.	0.4	0
287	157â€ƒPathogenesis of Epstein-Barr Virus-driven lymphomas of HIV+ patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 67.	0.9	0
288	Role of non-coding RNAs in resistance to targeted therapies in cutaneous melanoma. European Journal of Cancer, 2016, 69, S74.	1.3	0

#	Article	IF	Citations
289	Role of the HIV matrix protein p17 in EBV-driven lymphomagenesis. European Journal of Cancer, 2016, 61, S67-S68.	1.3	0
290	Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e242.	0.4	0
291	INTRANODAL TREATMENT WITH IFNÎ‘-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematological Oncology, 2019, 37, 317-318.	0.8	0
292	831 Bortezomib-induced immunogenic cell death enhances immune response in melanoma. Journal of Investigative Dermatology, 2019, 139, S143.	0.3	0
293	456 Bortezomib induces immunogenic cell death in melanoma and enhances immune responses in vivo. Journal of Investigative Dermatology, 2019, 139, S293.	0.3	0
294	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.2	0
295	Recent Advancements in Hematology: Knowledge, Methods and Dissemination. Hemato, 2020, 1, 5-6.	0.2	0
296	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
297	Abstract 1443: CHKing melanoma: CHK1 inhibitor +low dose hydroxyurea triggers immunogenic cell death and immunostimulatory cytokine expression to drive an anti-tumor immune response. , 2021, , .		0
298	Abstract 272: Glycomics: Protein glycosylation changes in the pathogenesis of head and neck cancer. , 2021, , .		0
299	Bidirectional induction of the cognate receptor-ligand Î±4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood, 2000, 95, 2397-2406.	0.6	0
300	Proteomic Profile of Human Gut Biopsies from Celiac Patients with and without Severe Complications.. Blood, 2006, 108, 3899-3899.	0.6	0
301	HER2 guided neoadjuvant treatment of advanced breast cancer: Clinico-biological correlations. Journal of Clinical Oncology, 2008, 26, 11559-11559.	0.8	0
302	Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation. Blood, 2008, 112, 623-623.	0.6	0
303	A phase II trial addressing the prevalence of chlamydial infection and eradication efficacy of antibiotic therapy in marginal zone lymphoma (OAMZL) and other lymphoproliferative disorders of the ocular adnexae (LPDOA).. Journal of Clinical Oncology, 2010, 28, e18520-e18520.	0.8	0
304	Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity.. Journal of Clinical Oncology, 2011, 29, e11083-e11083.	0.8	0
305	P3-14-25: Neoadjuvant Trastuzumab and Paclitaxel Combination Induces a High Rate of Pathological Complete Responses in Locally Advanced Breast Cancer by Exploiting Host Antitumor Immunity.. , 2011, , .		0
306	Association of Human Herpesvirus 6 with Human Tumors. Infectious Agents and Pathogenesis, 1995, , 313-326.	0.1	0

#	Article	IF	Citations
307	Abstract 1196: Epigenetic drugs modulate long noncoding RNAs expression in BRAF inhibitor-resistant melanoma. , 2017, , .		0
308	Abstract 1839: Suppression of Spry1 sensitizes cutaneous melanoma to BRAF-targeted therapy. , 2018, , .		0
309	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	0.6	0
310	Abstract B12: Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition. , 2020, , .		0
311	Pathogenesis of human reactive-appearing "non-monomorphous" malignant lymphoproliferative disorders: a hypothesis. Tumori, 1992, 78, 221-7.	0.6	0
312	Activation by point mutation of Ki-ras gene occurring in transfected human normal DNA. Tumori, 1988, 74, 499-506.	0.6	0
313	The role of molecular analyses of B-cell and T-cell clonality in the study of B-cell lymphomagenesis. Clinical and Experimental Rheumatology, 1996, 14 Suppl 14, S21-9.	0.4	0